| Donors | Sex | Clinical diagnosis | Age | Stage at diagnosis |  | Outcome | |
---|---|---|---|---|---|---|---|---|
Subtype | Bulky/non-bulky | Treatment | ||||||
Good outcome | GO1 | F | NS | UNSP | 29 | IV | ABVD | PFS |
GO2 | F | NS | B | 41 | IIA | Stanford V + Rad | PFS | |
GO3 | F | NS | NB | 79 | IA | ABVD + Rad | PFS | |
GO4 | F | NS | B | 22 | IIA | Stanford V + Rad | PFS | |
GO5 | M | NS | NB | 43 | IIA | ABVD | PFS | |
GO6 | M | NS | B | 20 | IIA | ABVD+R | PFS | |
GO7 | F | NS | NB | 64 | IIA | ABVD | PFS | |
GO8 | F | NS | B | 51 | IIIB | ABVD + Rad | PFS | |
GO9 | F | NS | UNSP | 54 | IV | ABVD | PFS | |
GO10 | F | NS | UNSP | 22 | IIA | ABVD | PFS | |
GO11 | F | NS | NB | 25 | IIA | ABVD | PFS | |
GO12 | F | NS | NB | 26 | IIB | ABVD | PFS | |
Poor outcome (CN) | PO1 | M | NS | UNSP | 48 | IIA | ABVD+R (1); R+Bendamustine (2) Zevalin(3) | Rel. |
PO2 | M | NS | B | 24 | II | ABVD (1); acc. BEACOPP (4X) std BEACOPP (2X)(2); Bendamustine + R (3); IGEV + Rad (4); BCPAT (5); CR PT | Ref. | |
PO3 | M | NS | UNSP | 25 | IIB | ABVD (1); ICE X 3 followed by BPCAT +Local Rad (2); CR PT | Rel. | |
PO4 | F | NS | B | 25 | IIA | ABVD (1); ICE (2X) (2); GVD+R+Rad (3); HCVAD 1A (4); F+ECPOCH TH2 Allogenic (5); CR PT | Ref. | |
PO5 | M | NS | B | 49 | IV | ABVD + R (1); ICE + R followed by BCPAT (2); R for EBV reactivation (3); CR PT | Ref. | |
PO6 | M | NS | NB | 20 | IIIB | ABVD+R (1); ICE X 2 (2); IGEV+R × 2 (3); Rad (4); BCPAT (5); CR | Ref. | |
Poor outcome (CE) | PO1 | M | NS | UNSP | 31 | IIIB | ABVD (1); ABVD (2); CPPV (3); DICE followed by BPCAT (4); HCVAD 1A + 1B (5); FMPAL (5) | Rel. |
PO2 | F | NS | UNSP | 23 | II | MOPP+ABVD (1); BEAC conditioning pre auto transplant (2); Rad (3); ICE X 2/ESHAP X 6 (4); | Rel. | |
PO3 | M | NS | UNSP | 21 | II | ABVD (1); ESHAP x 1 followed by BCPAT (2); Gemcitabine +Navelbine (3); HCVAD X 3A’S followed by FMPAL (4); DLI infusion (5); Revlamid+DLI infusion (6); | Rel. | |
PO4 | F | NS | B | 20 | IIA | ABVD+Rad (1); ICE+ auto transplant (2); bone resection+Rad (3); WU protocol phase II Revlamid (4); TH2 Study (EPOCH+FR) NCI protocol followed by BEACOPP pre transplant (5); (No rel.) | Rel. | |
PO5 | M | NS | UNSP | 30 | IIB | ABVD + Rad (1); ICE + Gemzar followed by BPCAT (2); ESHAP X 3 (3); HCVAD X 5 followed by FMPAL (4); Bendamustine (SK Protocol) 08–041 (5) | Rel. | |
PO6 | M | NS | UNSP | 49 | IIIB | ABVD (1); ICE followed by BCPAT; GVD + R (3); Revlamid (4) SGN-40 × 2 cycles (5); (PD) | Rel. | |
PO7 | M | NS | UNSP | 21 | IIA | ABVD (1); ESAHP (2); IGEV (3); BEAC + Rad (4); GDP; R+MOPP (5); died of PD. | Rel. |